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Abstract B7H1 and B7H4 overexpression is associated
with inhibition of the immune system in many solid
tumors, and altogether with CD200 molecule plays an
important role in tumor invasion by promoting malignant
transformation. However, there is no report about impact of
these molecules on laryngeal squamous cell carcinoma.
The objective of the present study was to assess by means
of flow cytometry the expression of B7H1, B7H4, CD200,
and CD200R on CD83? monocyte-derived dendritic cells
(Mo-DC), pulsed with autologous tumor cell lysates
(aTCL) in patients who suffer from G1, G2, or G3 lar-
yngeal carcinoma (LC, n = 60) in comparison to healthy
donors (HD, n = 15). It has been demonstrated that median
value of the percentages of CD83? B7H1?, CD83?
B7H4?, and CD83? CD200? cells were higher in LC
patients than HD (p = 0.041, p B 0.0001, and p = 0.02,
respectively). Mean fluorescence intensity (MFI) of
CD200, CD200R, B7H1, and B7H4 on the Mo-DC pulsed
with aTCL of the patients was also higher than on the Mo-
DC of HD (p B 0.0001, p B 0.0001, p = 0.002, and
p B 0.0001, respectively). The highest MFI levels of all
molecules were noted in grade 3 LC. The aforementioned
results prove that there is a relation between the presence of
laryngeal cancer and the expression of B7H1, B7H4,
CD200, and CD200R regulatory molecules on the CD83?
Mo-DC pulsed with autologous cancer cell lysates. Strong
association of LC grade and the tested antigens expression
suggests a critical role for these proteins in LC biology.
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Introduction
Laryngeal cancer is one of the most commonly occurring
malicious cancers of head and neck region, with squamous
cell carcinoma as the predominant histologic type [1, 2]. In
spite of their constant development, the classical thera-
peutic methods, such as surgical procedures or radiother-
apy are not sufficiently effective in prolonging the survival
time of cancer patients and improving the quality of their
lives [3]. Therefore, the increasing morbidity and unsatis-
factory effects of treatment, especially in cases of advanced
laryngeal carcinoma (LC), stimulate the researchers to
develop new more effective therapy schemes including
immunotherapy with the use of the dendritic cells (DC)
and/or monoclonal antibodies [4]. Unfortunately, an opti-
mal method of treatment with DC has not been developed
yet due to the limited knowledge of the biology of DC, the
influence of cancer antigens on their functions, and the
expression of co-stimulatory molecules which are extre-
mely vital as far as the interaction of DC with other cells is
concerned [5].
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B7H1 and B7H4 molecules belong to newly discovered
proteins from B7 family. B7H1 molecule demonstrates
hindering properties toward the immunological response of
T lymphocytes [6]. B7H4 molecule was identified in 2003
as a co-stimulatory molecule which is vital in the process
of hindering the proliferation of T lymphocytes and
blocking the production of cytokines by Th1 and Th2
subpopulations. Its high expression on the surface of cells
of some cancers may lead to an assumption that it is a
marker of carcinogenesis [7]. CD200 (formerly OX2) is a
type 1a membrane protein with two extracellular immu-
noglobulin superfamily domains, a single transmembrane
region, and a short cytoplasmic tail [8, 9], broadly
expressed on a variety of cell types, such as some DC,
thymocytes, T and B lymphocytes, neurons, kidney
glomeruli, syncytiotrophoblasts, and endothelial cells [10],
which delivers immunoregulatory signals through binding
to receptors expressed on monocytes/myeloid cells,
including monocyte-derived dendritic cells (Mo-DC), and
T lymphocytes. Signals delivered through the
CD200:CD200R axis have been shown to play an impor-
tant role in the regulation of anti-tumor immunity. Over-
expression of CD200 has been reported in a number of
malignancies and on cancer stem cells [11] and this mol-
ecule may play roles in local tumor invasion as well as
augments the metastatic capacity of squamous cell carci-
noma [12].
The main aim of the present study was to assess the
expression of B7H1, B7H4, CD200 and CD200R on
CD83? Mo-DC, pulsed with autologous tumor cell lysates
(aTCL), of patients who suffer from LC in comparison to
healthy donors (HD). To the best of our knowledge, the
present publication is the first to describe the mentioned
issue. Thus far, the expression of the aforementioned
molecules has not been assessed yet on DC in patients with
LC. The analysis seems to be essential for many reasons—
it will allow us to determine whether it is possible to derive
fully efficient DC from patients with LC, which respond to
cancer antigens, and what is the influence of LC antigens
on Mo-DC. We have also assessed the impact of LC in
various histological grades on the expression of B7H1,
B7H4, CD200, and CD200R molecules.
Materials and methods
Patients and healthy controls
Sixty male patients treated surgically for primarily diag-
nosed squamous cell carcinoma of the larynx, without
preoperative treatment, were included in the study. The
diagnosis of squamous cell carcinoma of the larynx was
established by histopathology of tumor samples. The mean
age of patients was 64.72 ± 9.29 years (ranging from 45 to
79 years; median 65.8).
Peripheral blood from 15 healthy male donors, at the
mean age of 57.68 ± 11.95 (ranging from 43 to 73 years;
median 59), was used as a control. In patients and HDs,
peripheral blood WBC was within the normal range
between 4 and 10 G/L.
None of the patients and controls had signs of infection
at the time of investigation and for a month before surgery
none had been taking drugs of known influence on the
immune system. None of the patients or HDs had under-
gone blood transfusion. Persons with allergic diseases in
anamnesis were excluded from the study. The research
protocol was approved by the local Ethics Committee and
all patients gave written informed consent.
Isolation of the peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated from heparinized venous blood of the patients and the
HDs by density gradient centrifugation using Gradisol-L
(Aqua Medica, Poland) and centrifuged for 20 min at
700 G. PBMCs were collected and washed twice in phos-
phate-buffered saline (PBS) without Ca2? or Mg2?
(Biochrom AG, Germany). Interphase cells were washed
twice in PBS without Ca2? or Mg2? (Biochrom AG,
Germany) and then resuspended at 0.5–1 9 106 cells.
Their viability was checked by Trypan Blue (Sigma-
Aldrich, Germany) staining in light microscopy.
Preparation of the neoplastic cell lysates
Laryngeal cancer tissue was obtained during surgical treat-
ment. Tumor samples (without necrotic areas) were digested
with 1 mg/ml of type I collagenase (Biochrome AG, Ger-
many), 1 mg/ml of type I deoxyribonucleic (Sigma, Ger-
many), and 0.1 mg/ml of hyaluronidase (Sigma, Germany)
and washed twice in RPMI 1640 (Biochrome, Germany).
Tumor cells were homogenized by five repeated cycles of
quick freezing (-80 C) and thawing (37 C). Large parti-
cles were removed by centrifugation and after that super-
natants were passed through a 20 lm pore filter.
Dendritic cells generation
Peripheral blood mononuclear cells were incubated with
anti-CD14 microbeads (Miltenyi-Biotec, Bergisch Glad-
bach, Germany) and passed through MACS separation
columns according to the manufacturer’s instructions. The
CD14? cell population was used to prepare Mo-DC. After
isolation, the CD14? cells were washed twice with PBS
and seeded into cell culture flasks. The CD14? cells were
cultured in RPMI 1640 medium (BioWhittaker,
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Walkersville, MD, USA) supplemented with 2 % human
albumin (Baxter, Austria), 100 IU/ml penicillin, 50 mg/ml
streptomycin, and 100 mg/ml neomycin (Sigma-Aldrich,
Germany) for 2 h in 37 C and 5 % CO2. After incubation,
the non-adherent cells were removed with PBS without
Ca2? and Mg2? (Biochrom AG, Germany). Adherent cells
were grown in the appropriate culture medium for 7 days.
On days 1, 3, and 5 of the culture, 1,000 IU/ml rhGM-CSF
(Leukine, Berlex, USA) and 500 IU/ml rhIL-4 (Miltenyi-
Biotec, Bergisch Gladbach, Germany) were added. The
cells were then divided into two equal parts and the first
part was assessed using flow cytometry method without
stimulation with tumor cell lysates. Tumor necrosis factor
a (rhTNF-a, Strathmann, Germany) at a concentration of
50 ng/ml and the aTCL were added to the second part
during the last 48 h of culture for the maturation and
pulsing of the Mo-DC.
The Mo-DC of healthy controls were generated as above
but were not pulsed with aTCL due to the absence of cancer
tissue in this group. Generated cells were then harvested
using Trypsin/EDTA solution (Biochrome, Germany).
Flow cytometric analysis
We used the followings monoclonal antibodies (mAb):
anti-CD83 FITC (BD Pharmingen, USA)/anti-B7H1 PE
(Biolegend, USA), anti-CD83 FITC (BD Pharmingen,
USA)/anti-B7H4 PE (Biolegend, USA), anti-CD83 FITC
(BD Bioscience, USA)/anti-CD200 PE (AbD Serotec,
USA), and anti-CD83 FITC (BD Bioscience, USA)/anti-
CD200R PE (AbD Serotec, USA). The cell phenotype
characterization was performed using a FACSCalibur
cytometer equipped with 488 nm argon laser (Becton–
Dickinson, USA) and analyzed with CellQuest Software
(Becton–Dickinson, USA). We collected 300,000 of events
in total. Cell debris and dead cells were excluded from the
analysis based on scatter signal.
Statistical analysis
Statistica 9 PL (Stat Soft Inc.) software was applied to
statistical analysis and Mann–Whitney U test was used.
Pearson’s linear correlation coefficient (r) was calculated
to disclose relationships between variables. All results are
showed as mean ± standard deviation (SD), medians, and
minimum and maximum values. p value \0.05 was con-
sidered statistically significant.
Results
The results are presented in the form of percentage values
of the cells with the expression of a given antigen and the
mean fluorescence intensity (MFI), which is the mean score
of the density of an expression of a given molecule on a
cell. Table 1 presents obtained results in G1, G2, G3 LC
patients, as in HD.
Our study revealed that the percentage of Mo-DC with
an expression of CD83 antigen in patients was statistically
lower than in HDs (median 91.28 %, range from 55.37 to
99.67 %; mean 87.53 ± 9.94 vs. 99.77 %, range from
99.41 to 99.86 %; mean 99.73 ± 0.14 %, p B 0.0001).
There was no difference between the percentages of Mo-
DC generated from patients with G1 and G2 LC
(p = 0.823). Lower frequencies of CD83? Mo-DC were
noted in patients with G3 LC in comparison to G1 LC
(p = 0.017). Significantly higher percentages of CD83?
Mo-DC were generated from HD than from G1, G2, and
G3 LC patients (p B 0.0001), and from G2 than G3 LC
patients (p = 0.005). Figure 1 illustrates observed results.
The differences of CD83 MFI values between the afore-
mentioned groups were also statistically significant
(p B 0.0001); higher in patients (median 308.44, range
from 201.23 to 628.26; mean 336.99 ± 115.39) than in
healthy individuals (median 192.01, range from 139.72 to
276.38; mean 199.22 ± 40.28). Figure 2 presents obtained
results.
It has been demonstrated that the percentage of Mo-DC,
stimulated with LC antigens, characterized by B7H1
expression, derived from the group of patients was signif-
icantly statistically higher than the frequencies of CD83?
B7H1? Mo-DC generated from the control group (median
87.81 %, range from 42.13 to 99.67 %; mean
79.26 ± 18.74 vs. 74.66 %, range from 42.95 to 94.72 %;
mean 71.27 ± 15.71 %, p = 0.041). Obtained results were
the most prominent in G3 LC patients (Fig. 3). The MFI of
B7H1 was also higher in patients than in HD (median
209.38, range from 78.84 to 623.68; mean
273.21 ± 151.50 vs. median 163.82, range from 102.93 to
261.15; mean 164.83 ± 46.07, p = 0.002). Differences
between B7H1 MFI on Mo-DC generated from patients in
G1, G2, G3, and from control group are presented in Fig. 4.
The percentage of mature DC with B7H4 expression
was also higher in the tested group than in the control
group (median 3.41 %, range from 1.14 to 16.16 %; mean
4.24 ± 3.38 vs. 1.82 %, range from 0.47 to 5.97 %; mean
1.96 ± 1.34 %, p B 0.0001). Differences between Mo-DC
generated from G1, G2, and G3 LC specimens were sig-
nificant. The highest frequencies of B7H4? Mo-DC were
found in poorly differentiated LC (Fig. 5). The obtained
MFI for B7H4 in the group of the individuals with LC was
as follows, median 42.99, range from 11.44 to 90.30; mean
44.76 ± 21.91, and statistically significantly higher than in
HD (median 4.02, range from 1.23 to 7.43; mean
4.11 ± 1.69, p B 0.0001), especially in the case of G3 LC
(Fig. 6).
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Table 1 Percentages of CD83?, CD83? CD200?, CD83?
CD200R?, CD83? B7H1?, and CD83? B7H4? Mo-DC generated
from laryngeal cancer patients in various histological grades (G1–G3)
and from healthy donors, and mean fluorescence intensity (MFI) of
analyzed molecules on Mo-DC
Minimum Maximum Mean Median Standard deviation
Laryngeal cancer grade 1 (G1), n = 15 patients
CD83? cells (%) 71.45 99.22 90.14 95.75 9.45
CD83 MFI 231.16 506.69 323.43 306.30 87.70
CD83? CD200? cells (%) 8.82 41.28 16.42 13.55 8.19
CD200 MFI 41.56 153.82 66.75 50.32 40.67
CD83? CD200R? cells (%) 29.03 87.27 67.92 74.87 18.41
CD200R MFI 188.63 451.68 274.16 242.47 88.16
CD83? B7H1? cells (%) 42.13 92.01 58.31 48.48 18.86
B7H1 MFI 78.84 281.38 154.47 164.92 70.93
CD83? B7H4? cells (%) 1.14 4.02 2.11 1.83 1.01
MFI B7H4 11.44 52.88 24.59 19.58 14.20
Laryngeal cancer grade 2 (G2), n = 23 patients
CD83? cells (%) 55.37 99.67 89.67 94.72 10.85
CD83 MFI 201.23 628.26 327.35 268.68 129.43
CD83? CD200? cells (%) 6.17 44.47 16.51 13.12 9.96
CD200 MFI 49.8 166.45 95.97 108.22 38.68
CD83? CD200R? cells (%) 45.93 95.34 76.28 79.49 14.46
CD200R MFI 239.42 504.09 318.91 289.80 78.04
CD83? B7H1? cells (%) 47.94 94.83 80.89 83.68 12.12
B7H1 MFI 153.08 335.72 214.97 201.77 43.60
CD83? B7H4 ?cells (%) 1.77 4.69 3.16 3.16 0.72
MFI B7H4 19.58 57.92 38.86 39.58 10.37
Laryngeal cancer grade 3 (G3), n = 22 patients
CD83? cells (%) 69.27 94.49 83.52 83.79 8.26
CD83 MFI 211.23 626.29 356.33 327.94 118.77
CD83? CD200? cells (%) 6.17 42.47 15.17 13.95 8.82
CD200 MFI 52.97 415.09 184.09 172.44 102.56
CD83? CD200R? cells (%) 33.75 94.01 70.32 82.15 18.17
CD200R MFI 254.34 874.18 603.04 549.01 214.64
CD83? B7H1? cells (%) 61.83 100.28 91.86 95.71 10.67
B7H1 MFI 175.03 623.68 415.05 424.93 155.81
CD83? B7H4? cells (%) 2.26 16.16 6.82 5.38 4.41
MFI B7H4 23.43 90.31 63.08 63.02 20.54
Healthy donors, n = 15 persons
CD83? cells (%) 99.41 99.86 99.73 99.77 0.14
CD83 MFI 139.72 276.38 199.23 192.00 40.28
CD83? CD200? cells (%) 6.12 22.68 11.22 10.79 3.85
CD200 MFI 14.41 24.47 18.16 18.25 2.83
CD83? CD200R? cells (%) 36.21 89.05 66.78 65.87 12.38
CD200R MFI 16.99 124.78 81.62 86.73 24.93
CD83? B7H1? cells (%) 42.95 94.72 71.27 74.66 15.70
B7H1 MFI 102.93 261.15 164.83 163.82 46.08
CD83? B7H4? cells (%) 0.47 5.97 1.96 1.82 1.34
MFI B7H4 1.23 7.43 4.11 4.02 1.69
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The proportion of CD83? CD200? cells in patients was
higher than in the healthy persons (median 13.71 %, range
from 6.17 to 44.47 %; mean 15.99 ± 8.99% vs. median
10.79 %, range from 6.12 to 22.68 %; mean
11.22 ± 3.85 %, p = 0.02), and the highest frequencies of
the described cells were noted in G3 LC (Fig. 7). Median
MFI value of CD200 antigen on the CD83? Mo-DC from
laryngeal cancer patients, stimulated with aTCL, amounted
to 109.82 (range from 41.56 to 415.09; mean
120.97 ± 84.68) and was statistically significantly higher
than on the unpulsed Mo-DC of HDs (median 18.25, range
from 14.41 to 24.47; mean 18.16 ± 2.83, p B 0.0001). In
patients suffering from poorly differentiated LC, the
highest MFI of CD200 molecule was noted (Fig. 8).
The control group was characterized by a lower per-
centage value of CD83? Mo-DC with CD200R antigen
expression (median 65.87 %, range from 36.21 to 89.05 %;
mean 65.78 ± 12.38 %) than individuals with laryngeal
cancer (median 79.86 %, range from 29.03 to 95.34 %;
mean 72.01 ± 16.98 %), but the statistical significance
Fig. 1 Assessment of the
frequencies of CD83? Mo-DC
in control group and laryngeal
cancer patients with grade 1,
grade 2, or grade 3 squamous
cells carcinoma of the larynx
Fig. 2 Assessment of the CD83
MFI values on Mo-DC in
control group and laryngeal
cancer patients with grade 1,
grade 2, or grade 3 squamous
cells carcinoma of the larynx
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was also not revealed (p = 0.277, Fig. 9). MFI of CD200
receptor expression on CD83? Mo-DC among the persons
with LC was considerably higher (mean 411.91 ± 205.74,
median 303.25, range from 188.63 to 874.18) than in the
control group (mean 81.62 ± 24.94, median 86.73, range
from 16.99 to 124.78, p B 0.0001) and the highest values
ware noted in G3 LC (Fig. 10).
Discussion
Patients with advanced cancer including squamous cell
carcinoma of the head and neck are known to be immu-
nologically compromised [13, 14]. Tumor cells can there-
fore escape from the immune responses by numerous
mechanisms, including the molecule B7H1, B7H4, and
Fig. 3 Assessment of the
frequencies of CD83? B7H1?
Mo-DC in control group and
laryngeal cancer patients with
grade 1, grade 2, or grade 3
squamous cells carcinoma of the
larynx
Fig. 4 Assessment of the B7H1
MFI values on Mo-DC in
control group and laryngeal
cancer patients with grade 1,
grade 2, or grade 3 squamous
cells carcinoma of the larynx
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CD200 that acts as a potent suppressor of CD200R-
expressing immune cells [15–17].
B7 molecules on the surface of antigen presenting cells
participate in the most important activation cycle in the
process of co-stimulation which constitutes a ‘second sig-
nal’ and is essential to activate T lymphocytes properly by
means of an interaction with CD28 molecule on T lym-
phocytes [18]. B7H1 demonstrates a strong expression of
activated DC, T lymphocytes, B lymphocytes, and mono-
cytes [19]. Allegedly, B7H1 molecule, which is present on
DC, influences the hindrance of T lymphocyte proliferation
dependent on TCR and the decrease in cytokine production
[20]. It can be significant while regulating the immune
response and the tolerance induction. In our research, it has
been observed statistically significantly higher percentage
of CD83? B7H1? cells in the group of the individuals
with LC. The tests conducted on an animal model [21]
demonstrated that the obstruction of B7H1 molecule will
result in the increase in interleukin 2 and interferon c
production. Our results suggest that Mo-DC of the LC
Fig. 5 Assessment of the
frequencies of CD83? B7H4?
Mo-DC in control group and
laryngeal cancer patients with
grade 1, grade 2, or grade 3
squamous cells carcinoma of the
larynx
Fig. 6 Assessment of the B7H4
MFI values on Mo-DC in
control group and laryngeal
cancer patients with grade 1,
grade 2, or grade 3 squamous
cells carcinoma of the larynx
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patients demonstrate a hindering influence on the T lym-
phocyte activation and proliferation by means of B7H1
molecule, which is overexpressed especially in LC grade 3.
B7H4 molecule, which interacts with its receptor, also
blocks the activation of T lymphocytes, the production of
cytokines and it limits cytotoxicity. The role of B7H4 is
also connected with the prevention of the apoptosis of
cancer cells. It has been demonstrated that interleukin 10
increases the expression of B7H4 on the surface of human
cells which presents an antigen and the factor which
stimulates the colonies of granulocytes and macrophages
and interleukin 4 decreases the expression of this molecule
[22]. Our study indicates that there is an overexpression of
B7H4 molecule on DC generated from patients with LC
and it corresponds with histological grade of LC.
Expression of CD200 has been implicated in multiple
types of human cancer including squamous cell carcinoma.
However, the impact of tumor expression of CD200 on
tumor immunity remains poorly understood and the
expression of the discussed molecules was not assessed on
Fig. 7 Assessment of the
frequencies of CD83? CD200?
Mo-DC in control group and
laryngeal cancer patients with
grade 1, grade 2, or grade 3
squamous cells carcinoma of the
larynx
Fig. 8 Assessment of the
CD200 MFI values on Mo-DC
in control group and laryngeal
cancer patients with grade 1,
grade 2, or grade 3 squamous
cells carcinoma of the larynx
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the Mo-DC of LC patients. CD200 molecule or its natural
ligand plays role in the delivery of a tolerizing signal. Our
study revealed that there is a significant relationship
between the presence and grade of LC, and the expression
of CD200 and CD200R molecules on the Mo-DC pulsed
with autologous cancer cell lysates. CD83? Mo-DC of
healthy controls present significantly lower MFI values of
CD200 and CD200R antigen expression than the same type
of cells after the stimulation. This finding means that
pulsing DC with laryngeal cancer tumor lysates would
increase the expression of CD200s known inhibitory effect
on myeloid cells and is quite surprising. Many studies
published before [23, 24] used the concept of pulsing DC
with autologous tumor lysates to elicit an effective anti-
tumor immune response. CD200 positive cells can inhibit
the stimulation of type-1 cytokine production by bone-
marrow-derived B7-1 (and B7-2) positive DC [25]. Other
data have implied an immunoregulatory role for CD200
expression, assayed by altered cytokine production in vitro
from cells stimulated in the presence or absence of
Fig. 9 Assessment of the
frequencies of CD83?
CD200R? Mo-DC in control
group and laryngeal cancer
patients with grade 1, grade 2,
or grade 3 squamous cells
carcinoma of the larynx
Fig. 10 Assessment of the
CD200R MFI values on Mo-DC
in control group and laryngeal
cancer patients with grade 1,
grade 2, or grade 3 squamous
cells carcinoma of the larynx
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expressed CD200 [26], which is nowadays widely accepted
as immunosuppressive factor. Hoek et al. [27] suggested
that binding of CD200 antigen with its specific receptor
CD200R on myeloid cells such as macrophages, is
responsible for down regulation of its activity, so the tissue
damage caused by macrophages might be naturally
reduced. Rosenblum et al. [28] marked that higher
expressions of CD200 were on DC that undergo apoptosis.
The most recent study, provided by Seeds et al. [29] shows
that CD200 knock-out macrophages produce more IFNa
than wild-type macrophages in response to stimulus, what
was consistent with CD200s known inhibitory effect on
myeloid cells. In contrast, blocking CD200 with an anti-
CD200 mAb resulted in reduced IFNa production. This
suggests there could be a differential effect of CD200 on
IFN induction pathways in DC and macrophages. More-
over, authors’ results support the hypothesis that CD200 is
involved in virally induced type I IFN induction.
A number of mAbs have been successfully used in solid
cancers. Because CD200 does not have a signaling domain
it appears that anti-CD200 Abs do not directly affect tar-
geted tumor cells, and Kretz-Rommel et al. [30] demon-
strated that the anti-CD200 mAbs, as expected, did not
inhibit tumor cell proliferation or directly induce cell death
[31]. Therefore, antagonistic anti-CD200 Abs are expected
to exert their effect by blocking immune suppression. Our
data indicate that also DC-based immunotherapy supported
by the use of mAb anti-CD200 may be effective in the
treatment of laryngeal cancer in future, but further studies
analyzing the influence of both mAb anti-CD200 and anti-
CD200R, and Mo-DC on autologous laryngeal cancer cell
cultures are essential.
Conclusions
Our results prove that there is a relation between the
presence of laryngeal cancer and the expression of B7H1,
B7H4, CD200, and CD200R regulatory molecules on the
CD83? Mo-DC pulsed with autologous cancer cell lysates.
Strong association of LC grade and the tested antigens
expression suggests a critical role for these proteins in LC
biology. The expression of the aforementioned tolerogenic
molecules on mature dendritic cells can be responsible for
the failure of the immunotherapy of squamous cell carci-
noma of the larynx with the use of DC, which have been
stimulated with autologous cancer cells lysates. The
implementation of the B7H1, B7H4, and CD200 inhibitors
to DC cancer vaccines seems to be appropriate, and could
make the immune system of a host more sensitive to cancer
antigens by means of unblocking the hindering influence of
the mentioned molecules on the cytotoxicity of T
lymphocytes.
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